| 1. |
- Mörtzell Henriksson, Monica, et al.
(author)
-
Adverse events in apheresis : an update of the WAA registry data
- 2016
-
In: Transfusion and apheresis science. - : Elsevier. - 1473-0502 .- 1878-1683. ; 54:1, s. 2-15
-
Research review (peer-reviewed)abstract
- Apheresis with different procedures and devices are used for a variety of indications that may have different adverse events (AEs). The aim of this study was to clarify the extent and possible reasons of various side effects based on data from a multinational registry. The WAA-apheresis registry data focus on adverse events in a total of 50846 procedures in 7142 patients (42% women). AEs were graded as mild, moderate (need for medication), severe (interruption due to the AE) or death (due to AE). More AEs occurred during the first procedures versus subsequent (8.4 and 5.5%, respectively). AEs were mild in 2.4% (due to access 54%, device 7%, hypotension 15%, tingling 8%), moderate in 3% (tingling 58%, urticaria 15%, hypotension 10%, nausea 3%), and severe in 0.4% of procedures (syncope/hypotension 32%, urticaria 17%, chills/fever 8%, arrhythmia/asystole 4.5%, nausea/vomiting 4%). Hypotension was most common if albumin was used as the replacement fluid, and urticaria when plasma was used. Arrhythmia occurred to similar extents when using plasma or albumin as replacement. In 64% of procedures with bronchospasm, plasma was part of the replacement fluid used. Severe AEs are rare. Although most reactions are mild and moderate, several side effects may be critical for the patient. We present side effects in relation to the procedures and suggest that safety is increased by regular vital sign measurements, cardiac monitoring and by having emergency equipment nearby.
|
|
| 2. |
- Peters, Björn, et al.
(author)
-
High Resistive Index in Transplant Kidneys Is a Possible Predictor for Biopsy Complications
- 2016
-
In: Transplantation Proceedings. - : Elsevier BV. - 0041-1345 .- 1873-2623. ; 48:8, s. 2714-2717
-
Journal article (peer-reviewed)abstract
- Background. Transplant kidney biopsies are performed to determine a histological diagnosis for specific patient treatment. The aim of this study was to investigate if Resistive Index (RI) could be a predictor for biopsy complications. Methods. In this study, 220 consecutive transplant kidney biopsies (136 men and 84 women; median age, 55.5 years) were prospectively included. RI (median, 0.7) was measured by use of ultrasound. Histological diagnoses and biopsy complications were registered. Biopsy needles were either 16- or 18-gauge. Biopsies were performed by radiologists and were carried out as an outpatient procedure (70%) or an inpatient procedure (30%). Usually three passes per biopsy were performed. Results. The overall complication rate was 6.8%, divided into major (4.5%) and minor (2.3%) complications. An RI >= 0.8 predicts major (13.3% versus 3.2%; risk ratio [RR], 4.2; confidence interval [CI], 1.3-14.1; P=.03) and overall biopsy complications (16.7% versus 5.3%; RR, 3.2; CI, 1.2-8.6; P=.04) compared with RI <0.8. In the group <0.8, RI correlated with age (r(s) = 0.28, P<.001) and systolic blood pressure (r(s) = 0.18, P=.02). In the group >= 0.8, RI correlated with degree of interstitial fibrosis (r(s) = 0.65, P=.006) and systolic blood pressure (r(s) = 0.40, P =.03). The multiple regression analysis showed that in the group <0.8, the RI correlated only with age (P<.001), whereas in the group >= 0.8, RI correlated only with the degree of interstitial fibrosis (P=.003). Conclusions. An RI >= 0.8 indicates greater risk for major and overall biopsy complications and should result in greater caution after biopsy.
|
|
| 3. |
- Stegmayr, Bernd, et al.
(author)
-
Distribution of indications and procedures within the framework of centers participating in the WAA apheresis registry
- 2017
-
In: Transfusion and apheresis science. - : Elsevier BV. - 1473-0502 .- 1878-1683. ; 56:1, s. 71-74
-
Journal article (peer-reviewed)abstract
- The WAA apheresis registry was established in 2003 and an increasing number of centers have since then included their experience and data of their procedures. The registry now contains data of more than 74,000 apheresis procedures in more than 10,000 patients. This report shows that the indications for apheresis procedures are changing towards more oncological diagnoses and stem cell collections from patients and donors and less therapeutic apheresis procedures. In centers that continue to register, the total extent of apheresis procedures and patients treated have expanded during the latest years.
|
|
| 4. |
- Wärme, Anna, et al.
(author)
-
High doses of erythropoietin stimulating agents may be a risk factor for AV-fistula stenosis
- 2019
-
In: Clinical Hemorheology and Microcirculation. - : IOS Press. - 1386-0291 .- 1875-8622. ; 71:1, s. 53-57
-
Journal article (peer-reviewed)abstract
- BACKGROUND: A native AV-fistula (AVF) for access in hemodialysis (HD) is preferable. Stenosis, a major hurdle, is associated with older age and diabetes mellitus. PURPOSE: This case-control study aimed to clarify if any medical and/or laboratory factors, that can be altered, could be associated to AVF stenosis. METHODS: 33 patients with a patent AVF without need of intervention during a two year period (Controls) were matched by diagnosis and age with 33 patients (Cases), that had at least one radiological invasive examination/intervention due to suspected AVF malfunction (case-control mode 2:1). RESULTS: Cases had higher weekly doses of Erythropoietin-Stimulating Agent (ESA) than Controls both before intervention (mean 8312 +/- 7119 U/w versus 4348 +/- 3790, p = 0.005) and after the intervention (7656 +/- 6795, versus 4477 +/- 3895, p = 0.018). Before intervention serum phosphate was higher in Cases while there was no significant difference in blood hemoglobin, weekly standard Kt/V, parathyroid hormone, calcium, albumin, C-reactive protein, smoking habits, BMI or other medication. CONCLUSION: Higher doses of ESA were administered in patients with AVF stenosis. Since ESA may cause local hypertrophic effects on the vascular endothelium, we should prescribe lower doses of ESA in patients at risk. Further studies should clarify such connection.
|
|
